Drug intelligence / Profile preview

ELN28

Development stage: Preclinical
Lead developer: Elasmogen

Overview

**ELN28** is an Elasmogen-developed, first-in-class dual-acting soloMER drug conjugate being developed for hidradenitis suppurativa. The conjugate binds and neutralizes soluble tumor necrosis factor alpha at inflamed tissue and uses a neutrophil elastase-cleavable linker to locally release the Janus kinase inhibitor tofacitinib, aiming to combine TNF alpha blockade with inflammation-site-restricted JAK inhibition while reducing systemic exposure to free tofacitinib. ([elasmogen.com](https://elasmogen.com/))

Targets

JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)JAK3 (Janus kinase 3)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on ELN28.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELN28.